Innovating Works

NEOSETAC

Financiado
New Selenium based Targeted Nanocapsules to treat Breast Cancer
The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting for 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer... The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting for 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer will be the focus of study being the most common cancers in women. It comprises of 10.4% of all the cancer incidences among women, causing 411 093 deaths per year overall the world. In Europe, there is more than twice of the amount of new breast cancer cases annually than new cases of cancer in any other place. The complexity of breast cancer makes it a big challenge for successful treatment. The NEOSETAC project will demonstrate the anti-cancer therapeutic potential of a novel Seleniumbased therapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancer treatment is until now limited in chemoprevention as dietary supplement. In this proposal, we aim to improve the therapeutic window, pharmacokinetic properties and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradable NPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Se compounds at desired location (tumor lesions and metastasis) is achieved. We also propose to functionalize NPs by cancer cell / cancer stem cell targeting ligands to further improve the therapeutic efficacy and prevent cancer recurrence after chemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover, targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se. ver más
31/10/2023
UAB
504K€
Duración del proyecto: 72 meses Fecha Inicio: 2017-10-02
Fecha Fin: 2023-10-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2023-10-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
MSCA-RISE-2017: Research and Innovation Staff Exchange
Cerrada hace 7 años
Presupuesto El presupuesto total del proyecto asciende a 504K€
Líder del proyecto
UNIVERSITAT AUTÒNOMA DE BARCELONA No se ha especificado una descripción o un objeto social para esta compañía.
Total investigadores 1266